{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:33:56Z","timestamp":1787160836930,"version":"build-2736575974"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Small cell lung cancer (SCLC) remains a biologically aggressive neuroendocrine carcinoma characterized by early metastatic spread, frequent relapse, and poor long-term survival. After several decades of limited progress, recent therapeutic advances have begun to reshape management across disease stages. In limited-stage SCLC, concurrent platinum-etoposide chemoradiotherapy remains the backbone of curative-intent treatment, while consolidation durvalumab after chemoradiotherapy has established a new standard for patients without disease progression. In extensive-stage SCLC, platinum-etoposide plus a PD-L1 inhibitor remains the preferred first-line approach. For selected patients, maintenance lurbinectedin plus atezolizumab and second-line tarlatamab have expanded treatment options beyond conventional cytotoxic chemotherapy. Intracranial management is also evolving, with greater emphasis on baseline brain magnetic resonance imaging, longitudinal surveillance, selective use of prophylactic cranial irradiation, stereotactic radiosurgery in appropriate patients, and neuroprotective strategies during whole-brain radiotherapy. Biologically, SCLC is increasingly recognized as a heterogeneous disease. Transcriptional subtypes, DLL3, B7-H3, SEZ6, SLFN11, and circulating tumor DNA are informing clinical trial design and may help refine future treatment selection. This review provides a clinically oriented overview of current standards and emerging therapeutic strategies in SCLC, with attention to evidence quality, toxicity, sequencing, and clinical applicability. It also discusses key unresolved questions that must be addressed before biomarker-directed and subtype-informed treatment can be integrated into routine practice.<\/jats:p>","DOI":"10.1007\/s00408-026-00927-6","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:36:58Z","timestamp":1787157418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update 2026: Management of Small Cell Lung Cancer"],"prefix":"10.1007","volume":"204","author":[{"given":"Mumtu","family":"Lalla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneet","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Buse Eglenen","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6051-2732","authenticated-orcid":false,"given":"Haiying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"927_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00428-4","author":"G Luo","year":"2025","unstructured":"Luo G, Zhang Y, Rumgay H, Morgan E, Langselius O, Vignat J et al (2025) Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(24)00428-4","journal-title":"Lancet Respir Med"},{"key":"927_CR2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21785","author":"Z Megyesfalvi","year":"2023","unstructured":"Megyesfalvi Z, Gay CM, Popper H, Pirker R, Ostoros G, Heeke S et al (2023) Clinical insights into small cell lung cancer: tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. https:\/\/doi.org\/10.3322\/caac.21785","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"927_CR3","doi-asserted-by":"publisher","first-page":"e70608","DOI":"10.1002\/cam4.70608","volume":"14","author":"D Uprety","year":"2025","unstructured":"Uprety D, Seaton R, Niroula A, Hadid T, Parikh K, Ruterbusch JJ (2025) Trends in the incidence and survival outcomes in patients with small cell lung cancer in the United States: an analysis of the SEER database. Cancer Med 14(3):e70608. https:\/\/doi.org\/10.1002\/cam4.70608","journal-title":"Cancer Med"},{"key":"927_CR4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4830","author":"JS Tseng","year":"2022","unstructured":"Tseng JS, Chiang CJ, Chen KC, Zheng ZR, Yang TY, Lee WC et al (2022) Association of smoking with patient characteristics and outcomes in small cell lung carcinoma, 2011\u20132018. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.4830","journal-title":"JAMA Netw Open"},{"key":"927_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31991-0","author":"TC Garcia","year":"2023","unstructured":"Garcia TC, Ruano-Ravina A, Candal-Pedreira C, Lopez-Lopez R, Torres-Duran M, Enjo-Barreiro JR et al (2023) Occupation as a risk factor of small cell lung cancer. Sci Rep. https:\/\/doi.org\/10.1038\/s41598-023-31991-0","journal-title":"Sci Rep"},{"key":"927_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.1117","author":"USPST Force","year":"2021","unstructured":"Force USPST, Krist AH, Davidson KW, Mangione CM, Barry MJ, Cabana M et al (2021) Screening for lung cancer: US preventive services task force recommendation statement. JAMA. https:\/\/doi.org\/10.1001\/jama.2021.1117","journal-title":"JAMA"},{"key":"927_CR7","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1592","author":"PL Thomas","year":"2021","unstructured":"Thomas PL, Madubata CJ, Aldrich MC, Lee MM, Owonikoko TK, Minna JD et al (2021) A call to action: dismantling racial injustices in preclinical research and clinical care of black patients living with small cell lung cancer. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1592","journal-title":"Cancer Discov"},{"key":"927_CR8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.32276","author":"K Zhou","year":"2021","unstructured":"Zhou K, Shi H, Chen R, Cochuyt JJ, Hodge DO, Manochakian R et al (2021) Association of race, socioeconomic factors, and treatment characteristics with overall survival in patients with limited-stage small cell lung cancer. JAMA Netw Open. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.32276","journal-title":"JAMA Netw Open"},{"key":"927_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60165-7","author":"JP van Meerbeeck","year":"2011","unstructured":"van Meerbeeck JP, Fennell DA, De Ruysscher DK (2011) Small-cell lung cancer. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(11)60165-7","journal-title":"Lancet"},{"key":"927_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00374-7","author":"T Sen","year":"2025","unstructured":"Sen T, Dotsu Y, Corbett V, Puri S, Sen U, Boyle TA et al (2025) Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(24)00374-7","journal-title":"Lancet Oncol"},{"key":"927_CR11","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0004-2024","author":"I Pandjarova","year":"2024","unstructured":"Pandjarova I, Mercieca D, Gijtenbeek RGP, Pereira JO, Fantin A, Castaldo N et al (2024) Small cell lung cancer and neuroendocrine tumours. Breathe (Sheff). https:\/\/doi.org\/10.1183\/20734735.0004-2024","journal-title":"Breathe (Sheff)"},{"key":"927_CR12","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2021.0058","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D\u2019Amico TA et al (2021) Small cell lung cancer, Version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. https:\/\/doi.org\/10.6004\/jnccn.2021.0058","journal-title":"J Natl Compr Canc Netw"},{"key":"927_CR13","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.17.18935","author":"Y Kishida","year":"2018","unstructured":"Kishida Y, Seki S, Yoshikawa T, Itoh T, Maniwa Y, Nishimura Y et al (2018) Performance comparison between (18)F-FDG PET\/CT plus brain MRI and conventional staging plus brain mri in staging of small cell lung carcinoma. AJR Am J Roentgenol. https:\/\/doi.org\/10.2214\/AJR.17.18935","journal-title":"AJR Am J Roentgenol"},{"key":"927_CR14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01435","author":"H Khurshid","year":"2023","unstructured":"Khurshid H, Ismaila N, Bian J, Dabney R, Das M, Ellis P et al (2023) Systemic therapy for small-cell lung cancer: ASCO-Ontario health (Cancer Care Ontario) guideline. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.23.01435","journal-title":"J Clin Oncol"},{"issue":"3","key":"927_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/s0169-5002(02)00072-7","volume":"37","author":"P Micke","year":"2002","unstructured":"Micke P, Faldum A, Metz T, Beeh KM, Bittinger F, Hengstler JG et al (2002) Staging small cell lung cancer: veterans administration lung study group versus international association for the study of lung cancer\u2013what limits limited disease? Lung Cancer 37(3):271\u2013276. https:\/\/doi.org\/10.1016\/s0169-5002(02)00072-7","journal-title":"Lung Cancer"},{"key":"927_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/nature14664","author":"J George","year":"2015","unstructured":"George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G et al (2015) Comprehensive genomic profiles of small cell lung cancer. Nature. https:\/\/doi.org\/10.1038\/nature14664","journal-title":"Nature"},{"key":"927_CR17","doi-asserted-by":"publisher","first-page":"103044","DOI":"10.1016\/j.ctrv.2025.103044","volume":"141","author":"H Wang","year":"2025","unstructured":"Wang H, Gao N, Wang L, Yang F, Liu B, Hu X et al (2025) Transformation from EGFR-mutant lung adenocarcinoma to small-cell lung cancer: from clonal evolution to lineage reprogramming. Cancer Treat Rev 141:103044. https:\/\/doi.org\/10.1016\/j.ctrv.2025.103044","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"927_CR18","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00428-026-04458-6","volume":"489","author":"M Zacharias","year":"2026","unstructured":"Zacharias M, John N, Kashofer K, Popper H (2026) Clinically actionable molecular alterations in Rb-retained small cell lung carcinoma variants. Virchows Arch 489(1):219\u2013224. https:\/\/doi.org\/10.1007\/s00428-026-04458-6","journal-title":"Virchows Arch"},{"key":"927_CR19","doi-asserted-by":"publisher","first-page":"e2500574","DOI":"10.1200\/PO-25-00574","volume":"9","author":"A Ajay","year":"2025","unstructured":"Ajay A, Ferdousi R, Joseph PL, Durer S, Rezvani A, Chen Z et al (2025) Comprehensive analysis of the value of dynamic changes in circulating tumor DNA in small cell lung cancer. JCO Precis Oncol 9:e2500574. https:\/\/doi.org\/10.1200\/PO-25-00574","journal-title":"JCO Precis Oncol"},{"key":"927_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34966","author":"M Agarwal","year":"2023","unstructured":"Agarwal M, Liu A, Almquist D, Langlais BT, Leventakos K, Yu NY et al (2023) Chemoimmunotherapy in patients with extensive-stage small cell lung cancer and a poor performance status. Cancer. https:\/\/doi.org\/10.1002\/cncr.34966","journal-title":"Cancer"},{"issue":"23","key":"927_CR21","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJM199212033272302","volume":"327","author":"JP Pignon","year":"1992","unstructured":"Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL et al (1992) A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 327(23):1618\u20131624. https:\/\/doi.org\/10.1056\/NEJM199212033272302","journal-title":"N Engl J Med"},{"issue":"6","key":"927_CR22","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1200\/JCO.1992.10.6.890","volume":"10","author":"P Warde","year":"1992","unstructured":"Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10(6):890\u2013895. https:\/\/doi.org\/10.1200\/JCO.1992.10.6.890","journal-title":"J Clin Oncol"},{"issue":"10","key":"927_CR23","doi-asserted-by":"publisher","first-page":"e2237699","DOI":"10.1001\/jamanetworkopen.2022.37699","volume":"5","author":"I Azar","year":"2022","unstructured":"Azar I, Yazdanpanah O, Jang H, Austin A, Kim S, Chi J et al (2022) Comparison of carboplatin with cisplatin in small cell lung cancer in US veterans. JAMA Netw Open 5(10):e2237699. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.37699","journal-title":"JAMA Netw Open"},{"issue":"7","key":"927_CR24","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1200\/JCO.1995.13.7.1632","volume":"13","author":"PA Bunn","year":"1995","unstructured":"Bunn PA, Crowley J, Kelly K, Hazuka MB, Beasley K, Upchurch C et al (1995) Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13(7):1632\u20131641. https:\/\/doi.org\/10.1200\/JCO.1995.13.7.1632","journal-title":"J Clin Oncol"},{"issue":"14","key":"927_CR25","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.1200\/JCO.2002.12.071","volume":"20","author":"M Takada","year":"2002","unstructured":"Takada M, Fukuoka M, Kawahara M, Sugiura T, Yokoyama A, Yokota S et al (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan clinical oncology group study 9104. J Clin Oncol 20(14):3054\u20133060. https:\/\/doi.org\/10.1200\/JCO.2002.12.071","journal-title":"J Clin Oncol"},{"key":"#cr-split#-927_CR26.1","doi-asserted-by":"crossref","unstructured":"Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC et al (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. In: Database of Abstracts of reviews of effects (DARE): quality-assessed reviews. Centre for Reviews and Dissemination","DOI":"10.1200\/JCO.2004.01.178"},{"key":"#cr-split#-927_CR26.2","unstructured":"(UK) [cited 2026 Aug 1]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK71205\/"},{"issue":"4","key":"927_CR27","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/annonc\/mdj","volume":"17","author":"D De Ruysscher","year":"2006","unstructured":"De Ruysscher D, Pijls-Johannesma M, Vansteenkiste J, Kester A, Rutten I, Lambin P (2006) Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. Ann Oncol 17(4):543\u2013552. https:\/\/doi.org\/10.1093\/annonc\/mdj094 PubMed PMID: 16344277","journal-title":"Ann Oncol"},{"issue":"1","key":"927_CR28","doi-asserted-by":"publisher","first-page":"CD004700","DOI":"10.1002\/14651858.CD004700.pub2","volume":"2004","author":"MCG Pijls-Johannesma","year":"2005","unstructured":"Pijls-Johannesma MCG, De Ruysscher D, Lambin P, Rutten I, Vansteenkiste JF (2005) Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2004(1):CD004700. https:\/\/doi.org\/10.1002\/14651858.CD004700.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"927_CR29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400403","author":"AT Turrisi 3rd","year":"1999","unstructured":"Turrisi AT 3rd, Kim K, Blum R, Sause WT, Livingston RB, Komaki R et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJM199901283400403","journal-title":"N Engl J Med"},{"key":"927_CR30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01359","author":"J Bogart","year":"2023","unstructured":"Bogart J, Wang X, Masters G, Gao J, Komaki R, Gaspar LE et al (2023) High-dose once-daily thoracic radiotherapy in limited-stage small-cell lung cancer: CALGB 30610 (Alliance)\/RTOG 0538. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.22.01359","journal-title":"J Clin Oncol"},{"issue":"5","key":"927_CR31","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ijrobp.2024.02.063","volume":"119","author":"GM Walls","year":"2024","unstructured":"Walls GM, Mistry H, Barlesi F, Bezjak A, Pechoux CL, O\u2019Brien M et al (2024) Long-term outcomes after concurrent once- or twice-daily chemoradiation in limited-stage small cell lung cancer: a brief report from the CONVERT trial. Int J Radiat Oncol Biol Phys 119(5):1386\u20131390. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.02.063","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"927_CR32","doi-asserted-by":"publisher","first-page":"110888","DOI":"10.1016\/j.radonc.2025.110888","volume":"207","author":"X Zhong","year":"2025","unstructured":"Zhong X, Liu Y, Ji Y, Wang L (2025) Thoracic radiotherapy schedules in limited-stage small cell lung cancer: a systematic review and network meta-analysis. Radiother Oncol 207:110888. https:\/\/doi.org\/10.1016\/j.radonc.2025.110888","journal-title":"Radiother Oncol"},{"key":"927_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00189-9","author":"J Yu","year":"2024","unstructured":"Yu J, Jiang L, Zhao L, Yang X, Wang X, Yang D et al (2024) High-dose hyperfractionated simultaneous integrated boost radiotherapy versus standard-dose radiotherapy for limited-stage small-cell lung cancer in China: a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(24)00189-9","journal-title":"Lancet Respir Med"},{"key":"927_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30742-7","author":"BH Gronberg","year":"2021","unstructured":"Gronberg BH, Killingberg KT, Flotten O, Brustugun OT, Hornslien K, Madebo T et al (2021) High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(20)30742-7","journal-title":"Lancet Oncol"},{"key":"927_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404873","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Spigel DR, Cho BC, Laktionov KK, Fang J, Chen Y et al (2024) Durvalumab after chemoradiotherapy in limited-stage small-cell lung cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2404873","journal-title":"N Engl J Med"},{"key":"927_CR36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8014","author":"D Barbie","year":"2025","unstructured":"Barbie D, Xie M, Broggi M, Cheng Y, Spigel DR, Senan S (2025) Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC). J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8014","journal-title":"J Clin Oncol"},{"key":"#cr-split#-927_CR37.1","unstructured":"Amgen A (2026) Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy [Clinical trial registration]. clinicaltrials.gov"},{"key":"#cr-split#-927_CR37.2","unstructured":"[cited 2026 Aug 1]. Clinical trial registration no.: NCT06117774. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06117774"},{"issue":"4","key":"927_CR38","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/NEJMoa2502099","volume":"393","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, Demirci U, Baka S, G\u00fcm\u00fc\u015f M et al (2025) Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med 393(4):349\u2013361. https:\/\/doi.org\/10.1056\/NEJMoa2502099","journal-title":"N Engl J Med"},{"issue":"22","key":"927_CR39","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"MJ Ahn","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M et al (2023) Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med 389(22):2063\u20132075. https:\/\/doi.org\/10.1056\/NEJMoa2307980","journal-title":"N Engl J Med"},{"key":"927_CR40","unstructured":"PrECOG LLC (2026) Phase III Trial of Consolidation Tarlatamab\u2009+\u2009Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (LS-SCLC) [Clinical trial registration]. clinicaltrials.gov. [cited 2026 Aug 4]. Clinical trial registration no.: NCT07637513. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07637513"},{"issue":"10","key":"927_CR41","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1200\/JCO.2015.63.8171","volume":"34","author":"CFJ Yang","year":"2016","unstructured":"Yang CFJ, Chan DY, Speicher PJ, Gulack BC, Wang X, Hartwig MG et al (2016) Role of adjuvant therapy in a population-based cohort of patients with early-stage small-cell lung cancer. J Clin Oncol 34(10):1057\u20131064. https:\/\/doi.org\/10.1200\/JCO.2015.63.8171","journal-title":"J Clin Oncol"},{"issue":"1","key":"927_CR42","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1200\/JCO-24-02245","volume":"43","author":"GP Kalemkerian","year":"2025","unstructured":"Kalemkerian GP, Khurshid H, Ismaila N (2025) Systemic therapy for small cell lung cancer guideline expert panel. Systemic therapy for small cell lung cancer: ASCO guideline rapid recommendation update. J Clin Oncol 43(1):101\u2013105. https:\/\/doi.org\/10.1200\/JCO-24-02245","journal-title":"J Clin Oncol"},{"key":"927_CR43","unstructured":"Alliance F (2026) Trials LLC adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer [Clinical trial registration]. clinicaltrials.gov. [cited 2026 Aug 4]. Clinical trial registration no.: NCT07149363. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07149363"},{"key":"927_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30065-1","author":"CL Pechoux","year":"2016","unstructured":"Pechoux CL, Sun A, Slotman BJ, De Ruysscher D, Belderbos J, Gore EM (2016) Prophylactic cranial irradiation for patients with lung cancer. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(16)30065-1","journal-title":"Lancet Oncol"},{"key":"927_CR45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908123410703","author":"A Auperin","year":"1999","unstructured":"Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJM199908123410703","journal-title":"N Engl J Med"},{"key":"927_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-022-02196-2","author":"Y Chen","year":"2022","unstructured":"Chen Y, Wang Y, Ren F, Huang Z, Tan B, Zhao Z et al (2022) Prophylactic cranial irradiation (PCI) versus active surveillance in patients with limited-stage small cell lung cancer: a retrospective, multicentre study. Respir Res. https:\/\/doi.org\/10.1186\/s12931-022-02196-2","journal-title":"Respir Res"},{"key":"927_CR47","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrae087","author":"K Ito","year":"2024","unstructured":"Ito K, Nakajima Y, Minakami S, Machitori Y, Hosomi Y, Hashimoto K et al (2024) Prophylactic cranial irradiation for limited-stage small-cell lung cancer in the modern magnetic resonance imaging era may be omitted: a propensity score-matched analysis. J Radiat Res. https:\/\/doi.org\/10.1093\/jrr\/rrae087","journal-title":"J Radiat Res"},{"key":"927_CR48","doi-asserted-by":"publisher","first-page":"102396","DOI":"10.1016\/j.eclinm.2023.102396","volume":"67","author":"K Gaebe","year":"2024","unstructured":"Gaebe K, Erickson AW, Li AY, Youssef AN, Sharma B, Chan KKW et al (2024) Re-examining prophylactic cranial irradiation in small cell lung cancer: a systematic review and meta-analysis. EClinicalMedicine 67:102396. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102396","journal-title":"EClinicalMedicine"},{"issue":"28","key":"927_CR49","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1200\/JCO.2009.23.1548","volume":"27","author":"MA Socinski","year":"2009","unstructured":"Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A et al (2009) Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. J Clin Oncol 27(28):4787\u20134792. https:\/\/doi.org\/10.1200\/JCO.2009.23.1548","journal-title":"J Clin Oncol"},{"issue":"23","key":"927_CR50","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ et al (2018) First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379(23):2220\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa1809064","journal-title":"N Engl J Med"},{"issue":"5","key":"927_CR51","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/onco.13752","volume":"26","author":"L Mathieu","year":"2021","unstructured":"Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X et al (2021) FDA approval summary: atezolizumab and durvalumab in combination with platinum-based chemotherapy in extensive stage small cell lung cancer. Oncologist 26(5):433\u2013438. https:\/\/doi.org\/10.1002\/onco.13752","journal-title":"Oncologist"},{"issue":"10212","key":"927_CR52","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D et al (2019) Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394(10212):1929\u20131939. https:\/\/doi.org\/10.1016\/S0140-6736(19)32222-6","journal-title":"Lancet"},{"issue":"12","key":"927_CR53","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G et al (2022) Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA 328(12):1223\u20131232. https:\/\/doi.org\/10.1001\/jama.2022.16464","journal-title":"JAMA"},{"issue":"7","key":"927_CR54","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","volume":"19","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P et al (2024) Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (RATIONALE-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol 19(7):1073\u20131085. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.008","journal-title":"J Thorac Oncol"},{"issue":"1","key":"927_CR55","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1001\/jamaoncol.2024.5019","volume":"11","author":"Y Cheng","year":"2025","unstructured":"Cheng Y, Zhang W, Wu L, Zhou C, Wang D, Xia B et al (2025) Toripalimab plus chemotherapy as a first-line therapy for extensive-stage small cell lung cancer: the phase 3 EXTENTORCH randomized clinical trial. JAMA Oncol 11(1):16\u201325. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5019","journal-title":"JAMA Oncol"},{"issue":"6","key":"927_CR56","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G et al (2022) Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23(6):739\u2013747. https:\/\/doi.org\/10.1016\/S1470-2045(22)00224-8","journal-title":"Lancet Oncol"},{"issue":"36","key":"927_CR57","doi-asserted-by":"publisher","first-page":"e44383","DOI":"10.1097\/MD.0000000000044383","volume":"104","author":"S Zhu","year":"2025","unstructured":"Zhu S, Liu J, Chen X, Jin S (2025) Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors? Medicine (Baltimore). 104(36):e44383. https:\/\/doi.org\/10.1097\/MD.0000000000044383","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"927_CR58","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1007\/s12325-023-02601-2","volume":"40","author":"J Goldschmidt","year":"2023","unstructured":"Goldschmidt J, Hart L, Scott J, Boykin K, Bailey R, Heritage T et al (2023) Real-world outcomes of trilaciclib among patients with extensive-stage small cell lung cancer receiving chemotherapy. Adv Ther 40(10):4189\u20134215. https:\/\/doi.org\/10.1007\/s12325-023-02601-2","journal-title":"Adv Ther"},{"issue":"5","key":"927_CR59","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.cllc.2021.03.010","volume":"22","author":"J Weiss","year":"2021","unstructured":"Weiss J, Goldschmidt J, Andric Z, Dragnev KH, Gwaltney C, Skaltsa K et al (2021) Effects of trilaciclib on chemotherapy-induced myelosuppression and patient-reported outcomes in patients with extensive-stage small cell lung cancer: pooled results from three phase II randomized, double-blind, placebo-controlled studies. Clin Lung Cancer 22(5):449\u2013460. https:\/\/doi.org\/10.1016\/j.cllc.2021.03.010 PubMed PMID: 33895103","journal-title":"Clin Lung Cancer"},{"issue":"9","key":"927_CR60","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jtho.2022.05.016","volume":"17","author":"M Reck","year":"2022","unstructured":"Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S et al (2022) Brief report: exploratory analysis of maintenance therapy in patients with extensive-Stage SCLC treated first line with atezolizumab plus carboplatin and etoposide. J Thorac Oncol 17(9):1122\u20131129. https:\/\/doi.org\/10.1016\/j.jtho.2022.05.016","journal-title":"J Thorac Oncol"},{"issue":"10495","key":"927_CR61","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/S0140-6736(25)01011-6","volume":"405","author":"L Paz-Ares","year":"2025","unstructured":"Paz-Ares L, Borghaei H, Liu SV, Peters S, Herbst RS, Stencel K et al (2025) Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet 405(10495):2129\u20132143. https:\/\/doi.org\/10.1016\/S0140-6736(25)01011-6","journal-title":"Lancet"},{"key":"927_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.1189","author":"R You","year":"2023","unstructured":"You R, Estrada J, Zhan J, Deegen P, Cooke K, Friedrich M et al (2023) 1189 Elucidating the effects of chemotherapy and immune checkpoint blockade on the activity of tarlatamab, a DLL3-targeting bispecific T cell engager molecule, in small cell lung cancer preclinical models. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2023-SITC2023.1189","journal-title":"J Immunother Cancer"},{"issue":"10","key":"927_CR63","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/S1470-2045(25)00480-2","volume":"26","author":"KG Paulson","year":"2025","unstructured":"Paulson KG, Lau SCM, Ahn MJ, Moskovitz M, Pogorzelski M, H\u00e4fliger S et al (2025) Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. Lancet Oncol 26(10):1300\u20131311. https:\/\/doi.org\/10.1016\/S1470-2045(25)00480-2","journal-title":"Lancet Oncol"},{"issue":"5","key":"927_CR64","doi-asserted-by":"publisher","first-page":"557","DOI":"10.21037\/jtd-2026-0607","volume":"18","author":"T Johnston","year":"2026","unstructured":"Johnston T, Breadner D, Raphael J (2026) Biomarker-driven maintenance therapy in extensive-stage-small cell lung cancer: evaluating the SWOG S1929 clinical trial. J Thorac Dis 18(5):557. https:\/\/doi.org\/10.21037\/jtd-2026-0607","journal-title":"J Thorac Dis"},{"issue":"3","key":"927_CR65","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jtho.2024.10.021","volume":"20","author":"NA Karim","year":"2025","unstructured":"Karim NA, Miao J, Reckamp KL, Gay CM, Byers LA, Zhao YQ et al (2025) Phase II randomized study of maintenance atezolizumab versus atezolizumab plus talazoparib in patients With SLFN11 positive extensive-stage SCLC: S1929. J Thorac Oncol 20(3):383\u2013394. https:\/\/doi.org\/10.1016\/j.jtho.2024.10.021","journal-title":"J Thorac Oncol"},{"issue":"4","key":"927_CR66","doi-asserted-by":"publisher","first-page":"e2500836","DOI":"10.1200\/PO-25-00836","volume":"10","author":"M Parma","year":"2026","unstructured":"Parma M, Wang K, Altintas Taslicay C, Shah K, Singhi EK, Rivera M et al (2026) Real-world experience of tarlatamab in extensive-stage small cell lung carcinoma showed promising systemic and intracranial efficacy with higher neurologic toxicity. JCO Precis Oncol 10(4):e2500836. https:\/\/doi.org\/10.1200\/PO-25-00836","journal-title":"JCO Precis Oncol"},{"issue":"29","key":"927_CR67","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.24.00553","volume":"42","author":"A Dowlati","year":"2024","unstructured":"Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K et al (2024) Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update. J Clin Oncol 42(29):3392\u20133399. https:\/\/doi.org\/10.1200\/JCO.24.00553","journal-title":"J Clin Oncol"},{"issue":"5","key":"927_CR68","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","volume":"26","author":"FJ Bolte","year":"2025","unstructured":"Bolte FJ, Dougherty SC, Danos AO, Lynch AC, Shvorak Y, Statler S et al (2025) Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases. Clin Lung Cancer 26(5):347\u2013353e1. https:\/\/doi.org\/10.1016\/j.cllc.2025.03.006","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"927_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cllc.2025.11.018","volume":"27","author":"U Joshi","year":"2026","unstructured":"Joshi U, Ong F, Melzer D, Ma JC, Saltos A, Chiappori A et al (2026) Optimizing tarlatamab delivery in small cell and neuroendocrine lung cancer: real-world insights into step-up dosing and prophylactic tocilizumab use. Clin Lung Cancer 27(2):48\u201358. https:\/\/doi.org\/10.1016\/j.cllc.2025.11.018","journal-title":"Clin Lung Cancer"},{"issue":"4","key":"927_CR70","doi-asserted-by":"publisher","first-page":"e2500836","DOI":"10.1200\/PO-25-00836","volume":"10","author":"M Parma","year":"2026","unstructured":"Parma M, Wang K, Altintas Taslicay C, Shah K, Singhi EK, Rivera M et al (2026) Real-world experience of tarlatamab in extensive-stage small cell lung carcinoma showed promising systemic and intracranial efficacy with higher neurologic toxicity. JCO Precis Oncol 10(4):e2500836. https:\/\/doi.org\/10.1200\/PO-25-00836","journal-title":"JCO Precis Oncol"},{"key":"927_CR71","doi-asserted-by":"publisher","DOI":"10.1200\/OP.2025.21.10_suppl.581","author":"M Waqas","year":"2025","unstructured":"Waqas M, Alley H, Mitchell L, Walsh WK, Osarogiagbon RU, Lammers PE (2025) Implementing a safe and effective process to deliver tarlatamab bispecific antibody treatment for patients with small cell cancer across a community healthcare system. JCO Oncol Pract. https:\/\/doi.org\/10.1200\/OP.2025.21.10_suppl.581","journal-title":"JCO Oncol Pract"},{"key":"927_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30461-7","author":"N Baize","year":"2020","unstructured":"Baize N, Monnet I, Greillier L, Geier M, Lena H, Janicot H et al (2020) Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(20)30461-7","journal-title":"Lancet Oncol"},{"issue":"5","key":"927_CR73","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","volume":"21","author":"J Trigo","year":"2020","unstructured":"Trigo J, Subbiah V, Besse B, Moreno V, L\u00f3pez R, Sala MA et al (2020) Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol 21(5):645\u2013654. https:\/\/doi.org\/10.1016\/S1470-2045(20)30068-1","journal-title":"Lancet Oncol"},{"issue":"16","key":"927_CR74","doi-asserted-by":"publisher","first-page":"3476","DOI":"10.1158\/1078-0432.CCR-24-3981","volume":"31","author":"CM Gay","year":"2025","unstructured":"Gay CM, Owonikoko TK, Byers LA, Choudhury NJ, Ahmed S, Cain Z et al (2025) Multidimensional analysis of B7 homolog 3 RNA expression in small cell lung cancer molecular subtypes. Clin Cancer Res 31(16):3476\u20133482. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-3981","journal-title":"Clin Cancer Res"},{"issue":"4","key":"927_CR75","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1200\/JCO-25-02142","volume":"44","author":"CM Rudin","year":"2026","unstructured":"Rudin CM, Johnson ML, Paz-Ares L, Nishio M, Hann CL, Girard N et al (2026) Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: primary analysis of the phase II IDeate-Lung01 trial. J Clin Oncol 44(4):261\u2013273. https:\/\/doi.org\/10.1200\/JCO-25-02142","journal-title":"J Clin Oncol"},{"issue":"6","key":"927_CR76","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, Fang W, Xue J, Meng X et al (2025) A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med 31(6):1949\u20131957. https:\/\/doi.org\/10.1038\/s41591-025-03600-2","journal-title":"Nat Med"},{"key":"927_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-026-04452-0","author":"LA Byers","year":"2026","unstructured":"Byers LA, Cho BC, Cooper AJ, Chiang AC, Han JY, Furqan M et al (2026) SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-026-04452-0","journal-title":"Nat Med"},{"issue":"9962","key":"927_CR78","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S0140-6736(14)61085-0","volume":"385","author":"BJ Slotman","year":"2015","unstructured":"Slotman BJ, van Tinteren H, Praag JO, Knegjens JL, El Sharouni SY, Hatton M et al (2015) Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet 385(9962):36\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(14)61085-0","journal-title":"Lancet"},{"issue":"7","key":"927_CR79","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1200\/JCO.1999.17.7.2092","volume":"17","author":"B Jeremic","year":"1999","unstructured":"Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A et al (1999) Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 17(7):2092\u20132099. https:\/\/doi.org\/10.1200\/JCO.1999.17.7.2092","journal-title":"J Clin Oncol"},{"issue":"10","key":"927_CR80","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1016\/j.jtho.2017.06.015","volume":"12","author":"EM Gore","year":"2017","unstructured":"Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE et al (2017) Randomized phase II study comparing prophylactic cranial irradiation alone to prophylactic cranial irradiation and consolidative extracranial irradiation for extensive-disease small cell lung cancer (ED SCLC): NRG oncology RTOG 0937. J Thorac Oncol 12(10):1561\u20131570. https:\/\/doi.org\/10.1016\/j.jtho.2017.06.015","journal-title":"J Thorac Oncol"},{"key":"927_CR81","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.ejca.2019.01.003","volume":"110","author":"S Rathod","year":"2019","unstructured":"Rathod S, Jeremic B, Dubey A, Giuliani M, Bashir B, Chowdhury A et al (2019) Role of thoracic consolidation radiation in extensive stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Eur J Cancer 110:110\u2013119. https:\/\/doi.org\/10.1016\/j.ejca.2019.01.003","journal-title":"Eur J Cancer"},{"key":"927_CR82","doi-asserted-by":"publisher","first-page":"111328","DOI":"10.1016\/j.radonc.2025.111328","volume":"216","author":"D Wr\u00f3bel","year":"2026","unstructured":"Wr\u00f3bel D, Wojewoda B, Zi\u00f3\u0142ek W, Potocki PM, Borowczak J (2026) Consolidative thoracic radiotherapy in the immunotherapy era for extensive-stage small cell lung cancer: a systematic review and meta-analysis with emphasis on brain and liver metastases. Radiother Oncol 216:111328. https:\/\/doi.org\/10.1016\/j.radonc.2025.111328","journal-title":"Radiother Oncol"},{"key":"927_CR83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071780","author":"B Slotman","year":"2007","unstructured":"Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, Hatton M et al (2007) Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa071780","journal-title":"N Engl J Med"},{"issue":"5","key":"927_CR84","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(17)30230-9","volume":"18","author":"T Takahashi","year":"2017","unstructured":"Takahashi T, Yamanaka T, Seto T, Harada H, Nokihara H, Saka H et al (2017) Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 18(5):663\u2013671. https:\/\/doi.org\/10.1016\/S1470-2045(17)30230-9","journal-title":"Lancet Oncol"},{"issue":"7","key":"927_CR85","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1001\/jamaoncol.2020.1271","volume":"6","author":"CG Rusthoven","year":"2020","unstructured":"Rusthoven CG, Yamamoto M, Bernhardt D, Smith DE, Gao D, Serizawa T et al (2020) Evaluation of first-line radiosurgery vs whole-brain radiotherapy for small cell lung cancer brain metastases: The FIRE-SCLC cohort study. JAMA Oncol 6(7):1028\u20131037. https:\/\/doi.org\/10.1001\/jamaoncol.2020.1271","journal-title":"JAMA Oncol"},{"key":"927_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00271-6","author":"K Gaebe","year":"2022","unstructured":"Gaebe K, Li AY, Park A, Parmar A, Lok BH, Sahgal A et al (2022) Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(22)00271-6","journal-title":"Lancet Oncol"},{"issue":"27","key":"927_CR87","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1200\/JCO-25-00056","volume":"43","author":"AA Aizer","year":"2025","unstructured":"Aizer AA, Tanguturi SK, Shi DD, Catalano PJ, Shin KY, Ricca I et al (2025) Stereotactic radiosurgery in patients with small cell lung cancer and 1\u201310 brain metastases: a multi-institutional, phase ii, prospective clinical trial. J Clin Oncol 43(27):2986\u20132997. https:\/\/doi.org\/10.1200\/JCO-25-00056","journal-title":"J Clin Oncol"},{"key":"927_CR88","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not114","author":"PD Brown","year":"2013","unstructured":"Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C et al (2013) Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol. https:\/\/doi.org\/10.1093\/neuonc\/not114","journal-title":"Neuro Oncol"},{"issue":"10","key":"927_CR89","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1200\/JCO.19.02767","volume":"38","author":"PD Brown","year":"2020","unstructured":"Brown PD, Gondi V, Pugh S, Tome WA, Wefel JS, Armstrong TS et al (2020) Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: phase III trial NRG oncology CC001. J Clin Oncol 38(10):1019\u20131029. https:\/\/doi.org\/10.1200\/JCO.19.02767","journal-title":"J Clin Oncol"},{"issue":"6","key":"927_CR90","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/JCO.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N et al (2021) Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol 39(6):619\u2013630. https:\/\/doi.org\/10.1200\/JCO.20.01055","journal-title":"J Clin Oncol"},{"key":"927_CR91","doi-asserted-by":"publisher","first-page":"v928","DOI":"10.1093\/annonc\/mdz394.089","volume":"30","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Goldman JW, Garassino MC, Dvorkin M, Trukhin D, Statsenko G et al (2019) PD-L1 expression, patterns of progression and patient-reported outcomes (PROs) with durvalumab plus platinum-etoposide in ES-SCLC: results from CASPIAN. Ann Oncol 30:v928\u2013v929. https:\/\/doi.org\/10.1093\/annonc\/mdz394.089","journal-title":"Ann Oncol"},{"issue":"3","key":"927_CR92","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","volume":"39","author":"CM Gay","year":"2021","unstructured":"Gay CM, Stewart CA, Park EM, Diao L, Groves SM, Heeke S et al (2021) Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell 39(3):346\u2013360e7. https:\/\/doi.org\/10.1016\/j.ccell.2020.12.014","journal-title":"Cancer Cell"},{"key":"927_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0133-9","author":"CM Rudin","year":"2019","unstructured":"Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J et al (2019) Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nat Rev Cancer. https:\/\/doi.org\/10.1038\/s41568-019-0133-9","journal-title":"Nat Rev Cancer"},{"key":"927_CR94","doi-asserted-by":"publisher","first-page":"107418","DOI":"10.1016\/j.lungcan.2023.107418","volume":"186","author":"SV Liu","year":"2023","unstructured":"Liu SV, Mok TSK, Nabet BY, Mansfield AS, De Boer R, Losonczy G et al (2023) Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer 186:107418. https:\/\/doi.org\/10.1016\/j.lungcan.2023.107418","journal-title":"Lung Cancer"},{"key":"927_CR95","doi-asserted-by":"publisher","first-page":"107924","DOI":"10.1016\/j.lungcan.2024.107924","volume":"196","author":"M Reck","year":"2024","unstructured":"Reck M, Dziadziuszko R, Sugawara S, Kao S, Hochmair M, Huemer F et al (2024) Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the phase III IMpower133 study and the phase III IMbrella A extension study. Lung Cancer 196:107924. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107924","journal-title":"Lung Cancer"},{"issue":"8","key":"927_CR96","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.21037\/jtd-2025-1306","volume":"17","author":"CC Cheng","year":"2025","unstructured":"Cheng CC, Ma LJ, Pang XM, Huang TS, Wang MF, Xu JY et al (2025) Efficacy and safety of poly ADP-ribose polymerase inhibitors (PARPis) in extensive-stage small-cell lung cancer (ES-SCLC) treatment: a systematic review and meta-analysis. J Thorac Dis 17(8):6201\u20136213. https:\/\/doi.org\/10.21037\/jtd-2025-1306","journal-title":"J Thorac Dis"},{"issue":"4","key":"927_CR97","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.ccell.2021.02.014","volume":"39","author":"A Thomas","year":"2021","unstructured":"Thomas A, Takahashi N, Rajapakse VN, Zhang X, Sun Y, Ceribelli M et al (2021) Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. Cancer Cell 39(4):566\u2013579e7. https:\/\/doi.org\/10.1016\/j.ccell.2021.02.014","journal-title":"Cancer Cell"},{"issue":"6","key":"927_CR98","doi-asserted-by":"publisher","first-page":"e2015654118","DOI":"10.1073\/pnas.2015654118","volume":"118","author":"U Jo","year":"2021","unstructured":"Jo U, Murai Y, Chakka S, Chen L, Cheng K, Murai J et al (2021) SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR\/CHK1 inhibitors. Proc Natl Acad Sci U S A 118(6):e2015654118. https:\/\/doi.org\/10.1073\/pnas.2015654118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"927_CR99","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.ccell.2020.05.001","volume":"38","author":"AS Ireland","year":"2020","unstructured":"Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB et al (2020) MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate. Cancer Cell 38(1):60\u201378e12. https:\/\/doi.org\/10.1016\/j.ccell.2020.05.001","journal-title":"Cancer Cell"},{"issue":"4","key":"927_CR100","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccell.2026.02.006","volume":"44","author":"J Duan","year":"2026","unstructured":"Duan J, Sun Y, Wang Q, Xing L, Wu L, Han L et al (2026) HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: results from the ARTEMIS-001 phase 1a\/b trial. Cancer Cell 44(4):846\u2013857e3. https:\/\/doi.org\/10.1016\/j.ccell.2026.02.006","journal-title":"Cancer Cell"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00927-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00927-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:37:01Z","timestamp":1787157421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-026-00927-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":102,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["927"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00927-6","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"5 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"62"}}